MacroGenics (NASDAQ: MGNX) has announced positive interim data from its ongoing Phase 2 LINNET study evaluating lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4, in patients with advanced clear cell gynecologic cancer (CCGC), today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
According to MacroGenics, single agent lorigerlimab demonstrated encouraging preliminary clinical activity in CCGC with a confirmed overall response rate of 25%, a disease control rate of 44%, and a manageable safety profile.
In a statement, Amir Jazaeri, MD, professor and vice chair for clinical research in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, and lead author of the poster, commented, “Clear cell gynecologic malignancies are notoriously aggressive, resistant to conventional platinum-based chemotherapies, and carry a poor prognosis. New targeted treatments are urgently needed. The 25% response rate and manageable tolerability profile in CCGC observed in the LINNET study represent a highly encouraging potential therapeutic signal for a single agent in this difficult-to-treat histological subtype.”
